Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European prospective investigation into cancer and nutrition study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kreimer Aimée R, Brennan Paul, Lang Kuhs Krystle A, Waterboer Tim, Clifford Gary, Franceschi Silvia, Michel Angelika, Willhauck-Fleckenstein Martina, Riboli Elio, Castellsagué Xavier, Hildesheim Allan, Fortner Renée Turzanski, Kaaks Rudolf, Palli Domenico, Ljuslinder Ingrid, Panico Salvatore, Clavel-Chapelon Françoise, Boutron-Ruault Marie-Christine, Mesrine Sylvie, Trichopoulou Antonia, Lagiou Pagona, Trichopoulos Dimitrios, Peeters Petra H, Cross Amanda J, Bueno-de-Mesquita H Bas, Vineis Paolo, Larrañaga Nerea, Pala Valeria, Sánchez María-José, Navarro Carmen, Barricarte Aurelio, Tumino Rosario, Khaw Kay-Tee, Wareham Nicholas, Boeing Heiner, Steffen Annika, Travis Ruth C, Quirós J Ramón, Weiderpass Elisabete, Pawlita Michael, Johansson Mattias
Аннотация
METHODS: Four hundred incident anogenital cancers (273 cervical, 24 anal, 67 vulvar, 12 vaginal, and 24 penile cancers) with prediagnostic blood samples (collected on average 3 and 8 years before diagnosis for cervix and noncervix cancers, respectively) and 718 matched controls were included. Plasma was analyzed for antibodies against HPV16 E6 and multiple other HPV proteins and genotypes and evaluated in relation to risk using unconditional logistic regression.
RESULTS: HPV16 E6 seropositivity was present in 29.2% of individuals (seven of 24 individuals) who later developed anal cancer compared with 0.6% of controls (four of 718 controls) who remained cancer free (odds ratio [OR], 75.9; 95% CI, 17.9 to 321). HPV16 E6 seropositivity was less common for cancers of the cervix (3.3%), vagina (8.3%), vulva (1.5%), and penis (8.3%). No associations were seen for non-type 16 HPV E6 antibodies, apart from anti-HPV58 E6 and anal cancer (OR, 6.8; 95% CI, 1.4 to 33.1). HPV16 E6 seropositivity tended to increase in blood samples drawn closer in time to cancer diagnosis.
CONCLUSION: HPV16 E6 seropositivity is relatively common before diagnosis of anal cancer but rare for other HPV-related anogenital cancers.